Antileukemic effects of perhexiline in T-ALL. (A) Dose-response cell viability curves (relative cell number equivalents compared with vehicle-treated controls) of T-ALL cell lines treated with perhexiline in triplicate. (B) Dose-response cell viability curves (relative cell number equivalents compared with vehicle-treated controls) of primary T-ALL patient samples treated with perhexiline in triplicate. (C,D) Representative images (C) and quantitative changes in tumor burden (D) assessed by luciferase in vivo bioimaging in NOTCH1-induced T-ALL-bearing mice treated with vehicle only or perhexiline. (E) Quantitative analysis of cellularity and leukemia infiltration (assessed by green fluorescent protein expression) in bone marrow from NOTCH1-induced T-ALL bearing mice (n = 6) treated with vehicle only or perhexiline. (F) Mouse spleens from NOTCH1-induced T-ALL bearing mice treated with vehicle only or perhexiline. Spleen weight and cellularity in NOTCH1-induced T-ALL-bearing mice treated with vehicle only or perhexiline. (G) Kaplan-Meier survival curves of mice harboring NOTCH1-induced T-ALL treated for 5 consecutive days with vehicle only (n = 10) or perhexiline (n = 10). Graphs indicate mean values; error bars represent standard deviation.